Rilpivirine and Dolutegravir Simultaneously Measured via RP-HPLC-PDA with Box–Behnken Design Application: A Study of Forced Degradation under Various Conditions

Simultaneous estimation of rilpivirine (RLVN) and dolutegravir (DTGR) in bulk and tablet dosage forms via RP-HPLC-PDA with a Box–Behnken design (BBD) has been performed in this study to develop a fast, precise, timely and cost-saving method for estimating RLVN and DTGR in bulk and tablet dosage form...

Full description

Bibliographic Details
Main Authors: Shadma Wahab, Mohammad Khalid, Sarfaraz Ahmad, Sherouk Hussein Sweilam
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Separations
Subjects:
Online Access:https://www.mdpi.com/2297-8739/10/3/185
_version_ 1797608972853706752
author Shadma Wahab
Mohammad Khalid
Sarfaraz Ahmad
Sherouk Hussein Sweilam
author_facet Shadma Wahab
Mohammad Khalid
Sarfaraz Ahmad
Sherouk Hussein Sweilam
author_sort Shadma Wahab
collection DOAJ
description Simultaneous estimation of rilpivirine (RLVN) and dolutegravir (DTGR) in bulk and tablet dosage forms via RP-HPLC-PDA with a Box–Behnken design (BBD) has been performed in this study to develop a fast, precise, timely and cost-saving method for estimating RLVN and DTGR in bulk and tablet dosage forms. The chromatographic conditions were optimized via the BBD, and the developed method was validated according to the ICH guidelines. Additionally, forced degradation studies were also conducted. RLVN and DTGR peaks were observed at retention times of 2.167 and 2.716 min, respectively, in a 6-min runtime. Kromasil 150 mm× 4.6 mm, 5 µm C 18 column was used. The flow rate of the mobile phase was 1.0 mL/min at a temperature of 30 °C. The mobile phase composition was a 0.1% OPA buffer and acetonitrile (ACN) in a 60:40 ratio. Elutes were measured at 260 nm (max) after being injected in a sample volume of 10 µL. The assay result of the marketed tablet was 99.19% and 99.09% for RLVN and DTGR, respectively. The results of forced degradation studies in different chemical environments conditions such as acid, base, dry heat, photo-stability, neutral, and oxidation conditions were observed for RLVN (5.96, 4.79, 3.27, 2.36, 0.99, and 4.35 in percentage degradation) and DTGR (5.67, 4.44, 4.09, 1.81, 0.43, and 4.28 in percentage degradation). The results of the validation parameters were within an acceptable range. The newly formed RP-HPLC-PDA method is novel, fast, precise, time-saving, and cost-effective.
first_indexed 2024-03-11T05:55:08Z
format Article
id doaj.art-3af6e787cf1d47ea83c4fada5c533494
institution Directory Open Access Journal
issn 2297-8739
language English
last_indexed 2024-03-11T05:55:08Z
publishDate 2023-03-01
publisher MDPI AG
record_format Article
series Separations
spelling doaj.art-3af6e787cf1d47ea83c4fada5c5334942023-11-17T13:50:13ZengMDPI AGSeparations2297-87392023-03-0110318510.3390/separations10030185Rilpivirine and Dolutegravir Simultaneously Measured via RP-HPLC-PDA with Box–Behnken Design Application: A Study of Forced Degradation under Various ConditionsShadma Wahab0Mohammad Khalid1Sarfaraz Ahmad2Sherouk Hussein Sweilam3Department of Pharmacognosy, College of Pharmacy, King Khalid University, Abha 62529, Saudi ArabiaDepartment of Pharmacognosy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, P.O. Box 173, Al-Kharj 11942, Saudi ArabiaDepartment of Clinical Pharmacy, Pharmacy Practice Research Unit (PPRU), College of Pharmacy, Jazan University, Jazan 45142, Saudi ArabiaDepartment of Pharmacognosy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, P.O. Box 173, Al-Kharj 11942, Saudi ArabiaSimultaneous estimation of rilpivirine (RLVN) and dolutegravir (DTGR) in bulk and tablet dosage forms via RP-HPLC-PDA with a Box–Behnken design (BBD) has been performed in this study to develop a fast, precise, timely and cost-saving method for estimating RLVN and DTGR in bulk and tablet dosage forms. The chromatographic conditions were optimized via the BBD, and the developed method was validated according to the ICH guidelines. Additionally, forced degradation studies were also conducted. RLVN and DTGR peaks were observed at retention times of 2.167 and 2.716 min, respectively, in a 6-min runtime. Kromasil 150 mm× 4.6 mm, 5 µm C 18 column was used. The flow rate of the mobile phase was 1.0 mL/min at a temperature of 30 °C. The mobile phase composition was a 0.1% OPA buffer and acetonitrile (ACN) in a 60:40 ratio. Elutes were measured at 260 nm (max) after being injected in a sample volume of 10 µL. The assay result of the marketed tablet was 99.19% and 99.09% for RLVN and DTGR, respectively. The results of forced degradation studies in different chemical environments conditions such as acid, base, dry heat, photo-stability, neutral, and oxidation conditions were observed for RLVN (5.96, 4.79, 3.27, 2.36, 0.99, and 4.35 in percentage degradation) and DTGR (5.67, 4.44, 4.09, 1.81, 0.43, and 4.28 in percentage degradation). The results of the validation parameters were within an acceptable range. The newly formed RP-HPLC-PDA method is novel, fast, precise, time-saving, and cost-effective.https://www.mdpi.com/2297-8739/10/3/185RP-HPLCPDA detectorBox–Behnken designICH guidelinesdegradation studiescost-effective
spellingShingle Shadma Wahab
Mohammad Khalid
Sarfaraz Ahmad
Sherouk Hussein Sweilam
Rilpivirine and Dolutegravir Simultaneously Measured via RP-HPLC-PDA with Box–Behnken Design Application: A Study of Forced Degradation under Various Conditions
Separations
RP-HPLC
PDA detector
Box–Behnken design
ICH guidelines
degradation studies
cost-effective
title Rilpivirine and Dolutegravir Simultaneously Measured via RP-HPLC-PDA with Box–Behnken Design Application: A Study of Forced Degradation under Various Conditions
title_full Rilpivirine and Dolutegravir Simultaneously Measured via RP-HPLC-PDA with Box–Behnken Design Application: A Study of Forced Degradation under Various Conditions
title_fullStr Rilpivirine and Dolutegravir Simultaneously Measured via RP-HPLC-PDA with Box–Behnken Design Application: A Study of Forced Degradation under Various Conditions
title_full_unstemmed Rilpivirine and Dolutegravir Simultaneously Measured via RP-HPLC-PDA with Box–Behnken Design Application: A Study of Forced Degradation under Various Conditions
title_short Rilpivirine and Dolutegravir Simultaneously Measured via RP-HPLC-PDA with Box–Behnken Design Application: A Study of Forced Degradation under Various Conditions
title_sort rilpivirine and dolutegravir simultaneously measured via rp hplc pda with box behnken design application a study of forced degradation under various conditions
topic RP-HPLC
PDA detector
Box–Behnken design
ICH guidelines
degradation studies
cost-effective
url https://www.mdpi.com/2297-8739/10/3/185
work_keys_str_mv AT shadmawahab rilpivirineanddolutegravirsimultaneouslymeasuredviarphplcpdawithboxbehnkendesignapplicationastudyofforceddegradationundervariousconditions
AT mohammadkhalid rilpivirineanddolutegravirsimultaneouslymeasuredviarphplcpdawithboxbehnkendesignapplicationastudyofforceddegradationundervariousconditions
AT sarfarazahmad rilpivirineanddolutegravirsimultaneouslymeasuredviarphplcpdawithboxbehnkendesignapplicationastudyofforceddegradationundervariousconditions
AT sheroukhusseinsweilam rilpivirineanddolutegravirsimultaneouslymeasuredviarphplcpdawithboxbehnkendesignapplicationastudyofforceddegradationundervariousconditions